Difference between revisions of "Fadrozole (Afema)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fadrozole-hydrochloride NCI Data Dictionary]: The hydrochloride salt of the...") |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fadrozole-hydrochloride NCI Data Dictionary]: The hydrochloride salt of the nonsteroidal aromatase inhibitor fadrozole with potential antineoplastic activity. Fadrozole specifically inhibits aromatase, blocking the aromatization of androstenedione and testosterone into estrone and estradiol, respectively, the final step in estrogen biosynthesis; the reduction in estrogen levels may inhibit growth in estrogen-dependent cancers. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fadrozole-hydrochloride NCI Data Dictionary]: The hydrochloride salt of the nonsteroidal aromatase inhibitor fadrozole with potential antineoplastic activity. Fadrozole specifically inhibits aromatase, blocking the aromatization of androstenedione and testosterone into estrone and estradiol, respectively, the final step in estrogen biosynthesis; the reduction in estrogen levels may inhibit growth in estrogen-dependent cancers. | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
| + | |||
| + | ==History of changes in PMDA indication== | ||
| + | *1995: Approved for the management of [[breast cancer]]. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' CGS-16949A | + | *'''Code name:''' CGS-16949A, FAD-286 |
*'''Brand name:''' Afema | *'''Brand name:''' Afema | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | [[Category:Aromatase inhibitors]] | + | [[Category:Aromatase inhibitors, second generation]] |
| − | [[Category: | + | |
| + | [[Category:Breast cancer medications]] | ||
| + | |||
| + | [[Category:PMDA approved in 1995]] | ||
Latest revision as of 15:09, 17 November 2023
Mechanism of action
From the NCI Data Dictionary: The hydrochloride salt of the nonsteroidal aromatase inhibitor fadrozole with potential antineoplastic activity. Fadrozole specifically inhibits aromatase, blocking the aromatization of androstenedione and testosterone into estrone and estradiol, respectively, the final step in estrogen biosynthesis; the reduction in estrogen levels may inhibit growth in estrogen-dependent cancers.
Diseases for which it is used
History of changes in PMDA indication
- 1995: Approved for the management of breast cancer.
Also known as
- Code name: CGS-16949A, FAD-286
- Brand name: Afema